Skip to content
sellWeak cluster of 210b5-1 plan

Matthew K Szot sold $25k of CVKD

Chief Financial Officer at Cadrenal Therapeutics, Inc.. 1,800 shares at an average of $13.99, traded Sep 29, 2025, filed Oct 1, 2025.

Warning score
15
Value
$25k
1,800 shares
Holdings after
17,133
-10% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    CFO
    +22
  • Trade size
    $25k at market
    +5
  • Share of holdings sold
    Sold 9.5% of holdings
    0
  • Cluster
    2 insiders selling within 14 days
    +8
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -2.8%, 3m -51.8%, 6m -65.1%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

CVKDOct 13, 2026 · close 1.00
Since filing Oct 1, 2025: -92.9%SPY +17.6% · excess -110.6%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001213900-25-094804, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Sep 29, 2025SOpen-market sale
Common Stock10b5-1
-100$14.00$1,40018,833Oct 1, 2025
Oct 1, 2025SOpen-market sale
Common Stock10b5-1
-1,700$13.99$24k17,133Oct 1, 2025

Related signals

Other insiders at Cadrenal Therapeutics, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
5Weak
CVKDsell10b5-1
Cadrenal Therapeutics, Inc.
Quang X Pham
Chairman and CEO
$22k
7,400 shares
-7%
11Weak
CVKDsell10b5-1
Cadrenal Therapeutics, Inc.
Quang X Pham
Chairman, CEO and Interim CFO
$34k
11,156 shares
-10%
11Weak
CVKDsell10b5-1
Cadrenal Therapeutics, Inc.
Quang X Pham
Chairman, CEO and Interim CFO
$40k
11,444 shares
-9%
5Weak
CVKDsell10b5-1
Cadrenal Therapeutics, Inc.
Quang X Pham
Chairman, CEO and Interim CFO
$13k
4,126 shares
-3%
18Weak
CVKDsell10b5-1
Cadrenal Therapeutics, Inc.
Quang X Pham
Chairman, CEO and Interim CFO
$70k
18,124 shares
-12%
20Weak
CVKDsell10b5-1
Cadrenal Therapeutics, Inc.
Quang X Pham
Chairman, CEO and Interim CFO
$93k
22,385 shares
-13%
11Weak
CVKDsell10b5-1
Cadrenal Therapeutics, Inc.
Quang X Pham
CEO and Chairman
$36k
8,285 shares
-5%
5Weak
CVKDsell10b5-1
Cadrenal Therapeutics, Inc.
Quang X Pham
CEO and Chairman
$3,075
652 shares
-0%
13Weak
CVKDsell10b5-1
Cadrenal Therapeutics, Inc.
Quang X Pham
CEO and Chairman
$69k
12,763 shares
-7%
5Weak
CVKDsell10b5-1
Cadrenal Therapeutics, Inc.
Quang X Pham
CEO and Chairman
$6,629
1,165 shares
-1%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Matthew K Szot sold $25k of CVKD | InsiderTell